Eton Pharmaceuticals Inc (ETON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has a cash flow conversion efficiency ratio of 0.242x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.41 Million) by net assets ($30.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Eton Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Eton Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eton Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BURFORD CAPITAL LTD
F:9BFA
|
-0.090x |
|
Dongguan Kingsun Optoelectronic Co Ltd
SHE:002638
|
-0.001x |
|
Guangzhou Automobile Group Co. Ltd
F:02G
|
0.001x |
|
Vanjee Technology Co Ltd
SHE:300552
|
0.001x |
|
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
|
0.045x |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
0.097x |
|
Guangdong Meiyan Jixiang Hydropower Co Ltd
SHG:600868
|
0.026x |
|
G-Shank Enterprise Co Ltd
TW:2476
|
0.034x |
Annual Cash Flow Conversion Efficiency for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ETON market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.15 Million | $10.52 Million | 0.402x | +914.39% |
| 2024-12-31 | $24.43 Million | $969.00K | 0.040x | -90.99% |
| 2023-12-31 | $15.48 Million | $6.82 Million | 0.440x | +19.45% |
| 2022-12-31 | $13.08 Million | $4.82 Million | 0.369x | +237.66% |
| 2021-12-31 | $17.63 Million | $-4.72 Million | -0.268x | +81.23% |
| 2020-12-31 | $15.66 Million | $-22.35 Million | -1.427x | +16.50% |
| 2019-12-31 | $10.55 Million | $-18.03 Million | -1.709x | -451.77% |
| 2018-12-31 | $26.30 Million | $-8.14 Million | -0.310x | +20.39% |
| 2017-12-31 | $12.13 Million | $-4.72 Million | -0.389x | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more